Determining the number of Ilb / Ilia glycoprotein receptors and expression of P-selectin on the surface of platelets using flow cytometry in patients with acute myeloid leukemia



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A study of the functional activity of platelets by flow cytometry is conducted in 11 patients with a diagnosis of AML are in clinical remission and 1 1 almost healthy volunteers. The functional activity of platelets was evaluated according to the dynamics of the number of glycoprotein receptors ( GP) IIb/IIIa on the platelet membrane and the percentage of platelets expressing P-selectin (CD62P) before and after induction 10 /тт ADP. The number of GP IIb/IIIa receptors on the platelet surface was evaluated by the mean fluorescence intensity. The average age of the subjects in the group of AML patients was 44,4±5,2 years in the control group, 38,5±6,8 years (p>0,05). In the group of AML patients platelet counts was 104,6±3,1 x109/L in the control group 210,5±20,8x109/L (p<0,01). After induction, increasing the number of receptors were observed in patients with AML, and they decrease in the control group. In patients with AML increase the number of receptors were observed after induction and the decrease in the control group. However, statistically significant differences (p>0,05) in the number of receptor GP IIb/IIIa before and after ADP stimulation in both groups have been identified. At the same time, there was no statistically significant difference (p<0,001) percent of CD62P expression on the platelet surface upon activation of ADP in AML patients and the control group. The percentage of CD62P expression on platelets in AML group increased average 2,1±0,23 times, and in the control group by 3,31±0,93 times. During the intergroup analysis it is not obtained statistically significant between the number of GP IIb/IIIa receptors and CD62P expression rate before and after induction of ADP in the studied groups. On the basis of obtained results it can be concluded that in this group of patients with AML functional activity of platelets does not differ from healthy volunteers.

Full Text

Restricted Access

About the authors

V. N Semelev

C.M. Kirov Military Medical Academy

Saint Petersburg, Russia

V. V Tyrenko

C.M. Kirov Military Medical Academy

Saint Petersburg, Russia

V. Yu Nikitin

C.M. Kirov Military Medical Academy

Saint Petersburg, Russia

I. A Sukhina

C.M. Kirov Military Medical Academy

Saint Petersburg, Russia

A. K Yurkin

C.M. Kirov Military Medical Academy

Saint Petersburg, Russia

L. A Tarakanova

C.M. Kirov Military Medical Academy

Saint Petersburg, Russia

N. Y Demyanenko

C.M. Kirov Military Medical Academy

Saint Petersburg, Russia

References

  1. Paulus J.M. Platelet size in man. Blood 1975; 46(3): 321-36.
  2. Stritt S., Nieswandt B. In vitro platelets in sight. Blood 2014; 124(12): 1849-50.
  3. Столяр М.А., Ольховский И.А. Диагностическое значение определения агрегационной активности тромбоцитов методом импедансометрии. Бюллетень лабораторной службы 2012; 15: 27-42.
  4. Machlus K.R., Thon J.N., Italiano J.E. Interpreting the developmental dance of the megakaryocyte: A review of the cellular and molecular processes mediating platelet formation. British Journal of Haematology 2014; 165(2): 227-36.
  5. Harker L.A., Roskos L.K., Marzec U.M. et al. Effects of megakaryocyte growth and development factor on platelet production,
  6. Philippova O.I., Koloskov A.V., Stolitsa A.A. Testing of platelet function (review), http://www.medline.ru/public/art/tom13/art40.html.
  7. Yip J., Shen Y., Berndt M.C. et al. Primary platelet adhesion receptors. IUBMB Life 2005; 57(2): 103-8.
  8. Newman P.J., Poncz M. Inherited disorders of platelets. In: Scriver C.R., Beaduet A.L., Sly W.S., editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill Professional; 1995. p. 3335-67.
  9. Bussel J.B., Kunicki T.J., Michelson A.D. Platelets: new understanding of platelet glycoproteins and their role in disease. Hematology 2000; 1: 222-40.
  10. Макацария А.Д., Бицадзе В.О. Тромбофилии и противотромботическая терапия в акушерской практике. Москва: Триада-Х; 2003.
  11. Воронина е.Н., Филипенко М.Л., Сергеевичев Д.С. и др. Мембранные рецепторы тромбоцитов: функции и полиморфизм. Вестник ВОГиС 2006; 10(3): 553-64.
  12. Berger C., Hartwell D.W., Wagner D.D. P-Selectin and platelet clearance. Blood 1998; 92: 4446-52.
  13. Маклецова С.А., Галявич А.С. Сердечно-сосудистые лекарственные средства и активация тромбоцитов. Казанский медицинский журнал 2003; 84(3): 204-7.
  14. Козловский В.И., Ковтун О.М., Сероухова О.П. и др. Методы исследования и клиническое значение агрегации тромбоцитов. Фокус на спонтанную агрегацию. Вестник ВГМУ 2013; 12(4): 79-91.
  15. Leytin V., Mody M., Semple J.W. et al. Flow cytometric parameters for characterizing platelet activation by measuring P-selectin (CD62P) expression: theoretical consideration and evaluation in thrombin-treated platelet populations. Biochem. Biophys. Res. Commun. 2000; 269: 85-90.
  16. Michelson A.D., Barnard M.R., Krueger L.A. et al. Evaluation of platelet function by flow cytometry. Methods 2000; 21(3): 259-70.
  17. Гусина А.А. Генетический полиморфизм гликопротеиновых рецепторов тромбоцитов как фактор риска тромбообразования. Кардиология в Беларуси 2009; 3(4): 17-24.
  18. Савченко В.Г., Паровичникова е.Н., Афанасьев Б.В. и др. Национальные клинические рекомендации по диагностике и лечению острых миелоидных лейкозов. Гематол. и трансфузиол. 2014; 59(1): 1-32.
  19. Баркаган З.С. ДВС-синдром и тромботическая тромбоцитопеническая пурпура при онкогематологических заболеваниях. Пробл. клинич. медицины. 2005; 1: 22-4.
  20. Абдулкадыров K.M. Неотложные состояния в гематологии. Вестн. гематологии. 2005; 1(1): 51-8.
  21. Baaten C.C., Moenen F.C., Henskens Y.M. et al. Multiple functional defects in platelets from thrombocytopenic cancer patients undergoing chemotherapy. J. Thromb. Haemost. 2016; 140(1): 171.
  22. Psaila B., Bussel J.B., Frelinger A.L. et al. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J. Thromb. Haemost. 2011; 9(11): 2302-10.
  23. Сироткина О.В., Боганькова Н.А., Ласковец А.Б. и др. Иммунологические методы в оценке функциональной активности тромбоцитов у больных с сердечно-сосудистыми заболеваниями. Медицинская иммунология 2010; 12(3): 213-218.
  24. Friedmann A.M., Sengul H., Lehmann H. et al. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus. Med. Rev. 2002; 16: 34-45.
  25. Psaila B., Petrovic A., Page L.K. et al. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood 2009; 114: 4777-83.
  26. Slichter S.J., Kaufman R.M., Assmann S.F. et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N. Engl. J. Med. 2010; 362: 600-13.
  27. Хаспекова С.Г., Зюряев И.Т., Якушкин В.В. и др. Средний объем тромбоцитов: взаимосвязи с агрегационной активностью тромбоцитов и уровнем экспрессии гликопротеинов IIB-IIIA и IB. Биомедицинская химия 2014; 60 (1): -94-108.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies